腹腔化疗在直肠癌术中应用的临床观察

发布时间：2018-04-23 22:34

本文选题：直肠癌 + 腹腔化疗　；参考：《重庆医科大学》2015年硕士论文

【摘要】：目的：探讨在直肠癌术中局部应用氟尿嘧啶缓释剂进行腹腔化疗的安全性及意义。方法：回顾性统计2012年5月至2014年5月在我院行Dixon术的直肠癌病人293例,置药组151例,对照组142例。比较两组患者术前最近一次血常规、肝肾功,术后7天的血常规、肝肾功,比较肠道功能恢复时间、术后住院天数,观察术后吻合口瘘、腹膜炎、肠梗阻、切口感染、吻合口出血、盆腔积液等发生情况。结果：两组患者术后WBC、PLT、ALT、AST较术前增高(P0.05),术后RBC、总白蛋白、白蛋白术后较术前降低(P0.05),但两组间变化比较,差异无统计学意义(P0.05)。植药组BUN术前与术后变化差异无统计学意义(P0.05),对照组术后BUN较术前有增高(P0.05),两组间BUN变化差异无统计学意义(P0.05)。两组术后Cr较术前均有降低(P0.05),植药组下降幅度低于对照组(P0.05)。两组肠道功能恢复时间、术后住院天数差异无统计学意义(P0.05)。两组并发症如吻合口瘘、腹膜炎、肠梗阻、切口感染、吻合口出血、盆腔积液、尿瘘、切口裂开发生率比较差异无统计学意义(P0.05)。结论：直肠癌术中局部应用氟尿嘧啶缓释剂进行腹腔化疗安全可行,以氟尿嘧啶缓释剂为代表的腹腔化疗可望在辅助化疗中发挥更大作用。
[Abstract]:Objective: to investigate the safety and significance of intraperitoneal chemotherapy with fluorouracil sustained-release agent in rectal cancer. Methods: from May 2012 to May 2014, 293 patients with rectal cancer underwent Dixon operation in our hospital, 151 patients in the drug insertion group and 142 patients in the control group were analyzed retrospectively. The last blood routine before operation, liver and kidney function, blood routine of 7 days after operation, liver and kidney function, recovery time of intestinal function, postoperative hospitalization days, postoperative anastomotic fistula, peritonitis, intestinal obstruction, incision infection were compared between the two groups. Anastomotic haemorrhage, pelvic effusion and so on. Results: after operation, the levels of WBC+ PLT alt and AST in the two groups were significantly higher than those before operation (P 0.05), but there was no significant difference between the two groups in the changes of RBC, total albumin and albumin after operation compared with those before operation (P 0.05), but there was no significant difference between the two groups (P 0.05). There was no significant difference in the changes of BUN between the two groups before and after operation (P 0.05), but the BUN in the control group was higher than that before operation (P 0.05). There was no significant difference in BUN between the two groups (P 0.05). The decrease of Cr in the two groups was lower than that in the control group (P 0.05), and the decrease was lower in the planting group than that in the control group (P 0.05). There was no significant difference in the recovery time of intestinal function and the length of hospitalization between the two groups (P 0.05). There was no significant difference in the incidence of anastomotic fistula, peritonitis, intestinal obstruction, incision infection, anastomotic bleeding, pelvic effusion, urinary fistula and incision rupture between the two groups (P 0.05). Conclusion: intraperitoneal chemotherapy with fluorouracil sustained-release agent is safe and feasible, and the intraperitoneal chemotherapy represented by fluorouracil sustained-release agent is expected to play a more important role in adjuvant chemotherapy.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R735.37

【相似文献】